Showing 151–175 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Wuhan Pulmonary Hospital
… new, effective, safe, and short-course anti-drug-resistant regimens. A 6-month short-course oral regimen containing pretomanid was launched in 2020 and was approved for marketing in China in March 2025. Currently, there have been multi-center studies on the treatment of rifampic…
Nelly Solomonia, K Vacharadze
…the all anti-TB drugs and to build an appropriate treatment regimens based on complete individual DST profile in timely manner. Initial TB treatment regimen prescribed based on gDST results not in all cases may be compliant with complete DST profile, which may be detected based o…
Hélène E. Aschmann, Allan Musinguzi, Jillian L. Kadota, Catherine Namale, Juliet Kakeeto, et al.
…le 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little is known about preferences of PLHIV for key features of TPT regimens. Methods: We conducted a discrete choice experiment among adult PLHIV engaged in care at an urban HIV clini…
Wenwen Sun, Qin Tang, Jie Wang, Jin‐Hui Yang, Fangyou Yu, et al.
Abstract Background: MDR-TB（multidrug-resistant tuberculosis） remains the challenge with low success rate of treatment. Pasiniazid had been applied in China for two decades, but relevant clinical studies are rare. To verify the efficacy and safety of a regimen containing pasiniaz…
Nisha Wanichwecharungruang, Weerinth Puyati, Thanyanuch Sanchat
Abstract Introduction: The 4-month rifapentine-moxifloxacin (HPMZ) regimen has recently been shown to be as effective as the standard 6-month rifampicin-based regimen for drug-susceptible pulmonary tuberculosis. Clinical trials reported serious adverse drug reactions (ADRs) in on…
Himanshi Khera, Tarun Narang, Seema Chhabra, Debajyoti Chhaterjee, Samir Malhotra, et al.
…pad. Groups of animals using different dosing schedules and regimens for bedaquiline are compared against WHO-MDT regimen. Additionally, drug interaction study for evaluating interaction with concomitantly administered drugs was carried out in Swiss albino mice. For clinical stud…
Soedarsono Soedarsono
… well as changes in the grouping of medicines used in DR-TB regimens in longer/individual regimens. Bedaquiline, delamanid, pretomanid, and sutezolid are new drugs which have been studied for their uses as anti-TB drugs (ATD). Bedaquilin and delamanid, which have passed phase 3 t…
Andrew Nunn
Tuberculosis drug regimens and their efficacies Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL conducts two stages of drug treatment for those with tuberculosis called 'STREAM'. In this clinical trial, stage 1 demonstrated that …
Hindol Mondal, Manasi Banerjee, Abheek Das, Somnath Maity
Introduction: Multidrug resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is a leading cause of death in India. To combat this, National TB Elimination Programme, erstwhile RNTCP) has launched “shorter oral bedaquiline (Bdq)-containing MDR/RR-TB regimen” from March 2021 rep…
Keertan Dheda, MBChB
This study aims to evaluate the impact of a new injection-free six-to-nine month treatment regimen of linezolid, bedaquiline, levofloxacin, pyrazinamide (PZA) and ethionamide/high dose isoniazid (INH) compared to the conventional empiric injection-based regimen. The secondary aim…
Richard E. Chaisson, MD
…drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will eff…
Jann-Yuan Wang, Ph.D.
…e very helpful for policy making in public health. Several regimens have been used in treating LTBI, including 9-month isoniazid, 4-month rifampin, 2-month rifampin plus pyrazinamide, and 3-month isoniazid plus rifampin. Among the 4 regimens, 2-month rifampin plus pyrazinamide h…
Christian Auer, Aastha Gupta, C. Malbacius, A. Ghafoor, Yulene Kock, et al.
BACKGROUND: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system …
Tom Yates, Daniel Grint
Treatment regimens for tuberculosis remain protracted and burdensome, both for patients to adhere to and for health-care providers to administer. Particularly, many current regimens for drug-resistant tuberculosis are poorly tolerated by patients and carry an unacceptable side-ef…
BLANC François-Xavier, MD, PhD, LAUREILLARD Didier, MD
DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 ce…
Auchynka V.P.
…dy the effectiveness of treatment with delamanid-containing regimens in patients with multidrug-resistant and extensively drug-resistant tuberculosis and comorbid cardiovascular diseases, to assess the frequency, structure, and severity of adverse events in the cardiovascular sys…
О В Родина, Sergey Evgenievich Borisov, Diana Ivanova
<b>Background:</b> The new regimens for MDR TB, presented by WHO in 2018, August, are promising, but their feasibility, depended on safety, isn’t tested enough in real-life conditions. <b>Methods:</b> The retrospective/prospective study include 205 pts with pulmonary MDR TB (18-7…
Liang Li
The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB. This is a single-arm, multicenter, phase #, open-label trial to evaluate the safety an…
Beijing Chest Hospital
WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the over…
Simbarashe G Takuva, MD, MSc.
This study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant pulmonary TB. The main goal is to see if a new drug called quabodepistat, when combined with other TB drug…
E. S. Ovsyankinа, Л. В. Панова, E. A. Krushinskaya, М. А. Багиров
…e: to evaluate the effectiveness of short-curse chemotherapy regimens for treatment of MDR/pre-XDR tuberculosis in combination with surgery in older children and adolescents. Subjects and Methods. 51 patients with MDR/pre-XDR respiratory tuberculosis aged 13-17 years were enrolled…
Jia-Yih Feng, Chin‐Chung Shu, Shu Min Lin, Ya-Wei Weng, Jui-Kuang Chen, et al.
… epidemic by 2030. Efficacious, safe, and shorter treatment regimens may significantly improve treatment success rates, and reduce TB incidence and mortality. The aim of this study is to evaluate the efficacy and safety of a short-course, 4-month regimen (2HZPM/2HPM) in the Asian…
Yanping Li, Linlin Song, Zhen Feng, Feng Sun, Wei Zhang
Abstract Introduction: Potential hepatotoxicity, particularly significant hyperbilirubinemia, is a major challenge to promoting the rifapentine-based 4-month regimen (2HPMZ/2PMZ) for drug-sensitive tuberculosis. A more detailed description of hepatotoxicity profiles during the ap…
М.В. Ураксина, E. P. Еremenko, Е. А. Бородулина, B. Borodulin
The main problem in the treatment of tuberculosis (TB) patients is the increase in drug resistance of M.tuberculosis, which is not always detected at the start of chemotherapy, which leads to inadequate and lengthy treatment. Research objective . Analysis of the treatment of newl…
О. М. Raznatovska, S. I. Tertishniy, V.G. Syusyuka, A.V. Fedorec, Т. К. Sahaidak, et al.
Background. According to World Health Organization (WHO), experimental studies performed in rats and rabbits have revealed no evidence of harmful side effects of bedaquiline to the fetus. WHO points out that, given the lack of adequate and controlled studies on the effects of bed…